Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Hull

Showing results (121-130 of 123) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 123 results.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2022
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
NPJ Vaccines|March 1, 2022
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapyZabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.
The Journal of Infectious Diseases|June 7, 2022
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose ResponsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Pageof 13

Showing results (121-130 of 123) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 123 results.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2022
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
NPJ Vaccines|March 1, 2022
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapyZabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.
The Journal of Infectious Diseases|June 7, 2022
People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose ResponsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Pageof 13